First-Wave-Logo-FINAL-RGB[1].jpg
First Wave BioPharma Announces Restructuring of Merger Consideration Payment Terms With Former Shareholders of First Wave Bio
November 16, 2021 07:00 ET | First Wave BioPharma, Inc.
BOCA RATON, Fla., Nov. 16, 2021 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ:FWBI), (“First Wave BioPharma,” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
AzurRx_Logo_CMYK.jpg
AzurRx BioPharma Activates New Clinical Trial Sites in India for Phase 2 RESERVOIR Trial Evaluating Niclosamide for the Treatment of COVID-19 Gastrointestinal Infections
September 10, 2021 08:30 ET | AzurRx BioPharma, Inc.
BOCA RATON, Fla., Sept. 10, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (“AzurRx” or the “Company”) (NASDAQ: AZRX), a company specializing in the development of targeted non-systemic, therapies...
AzurRx_Logo_CMYK.jpg
AzurRx BioPharma Announces Positive Results from Independent Data Monitoring Committee Review of Safety Data from Part 1 of RESERVOIR Phase 2 Clinical Trial of Niclosamide for the Treatment of COVID-19 Gastrointestinal Infections
September 09, 2021 08:30 ET | AzurRx BioPharma, Inc.
Review of Interim Safety Data Concluded with Favorable Recommendation to Continue RESERVOIR Trial as Planned Part 2 of RESERVOIR Trial to Enroll Up to 150 Patients to Evaluate Efficacy of FW-1022 and...
AzurRx_Logo_CMYK.jpg
AzurRx BioPharma to Present at the Virtual H.C. Wainwright 23rd Annual Global Investment Conference
September 07, 2021 16:30 ET | AzurRx BioPharma, Inc.
BOCA RATON, Fla., Sept. 07, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (“AzurRx” or the “Company”) (NASDAQ: AZRX), a company specializing in the development of targeted, non-systemic therapies...
AzurRx_Logo_CMYK.jpg
AzurRx BioPharma Announces Appointment of Terry Coelho to its Board of Directors
August 16, 2021 08:00 ET | AzurRx BioPharma, Inc.
BOCA RATON, Fla., Aug. 16, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (“AzurRx” or the “Company”) (NASDAQ: AZRX), a company specializing in the development of targeted non-systemic, therapies...
AzurRx_Logo_CMYK.jpg
AzurRx BioPharma Completes Initial Cohort Enrollment into Part 1 of its RESERVOIR Phase 2 Clinical Trial of Niclosamide for the Treatment of COVID-19 Gastrointestinal Infections
August 12, 2021 07:00 ET | AzurRx BioPharma, Inc.
BOCA RATON, Fla., Aug. 12, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (“AzurRx” or the “Company”) (NASDAQ: AZRX), a company specializing in the development of targeted, non-systemic therapies...
AzurRx_Logo_CMYK.jpg
AzurRx BioPharma Adds New Clinical Trial Sites in Ukraine for Phase 2 RESERVOIR Clinical Trial of Niclosamide for the Treatment of COVID-19 Gastrointestinal Infections
August 10, 2021 07:00 ET | AzurRx BioPharma, Inc.
BOCA RATON, Fla., Aug. 10, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (“AzurRx” or the “Company”) (NASDAQ: AZRX), a company specializing in the development of targeted non-systemic,...
AzurRx_Logo_CMYK.jpg
AzurRx BioPharma Announces Closing of $5.75 Million Bought Deal Offering and Exercise in Full of Underwriter’s Option to Purchase Additional Shares
July 27, 2021 16:30 ET | AzurRx BioPharma, Inc.
BOCA RATON, Fla., July 27, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX), (“AzurRx” or the “Company”), a clinical stage biopharmaceutical company specializing in the development of...
AzurRx_Logo_CMYK.jpg
AzurRx BioPharma CEO James Sapirstein to Present at 2021 BIO Digital
June 08, 2021 07:00 ET | AzurRx BioPharma, Inc.
BOCA RATON, Fla., June 08, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX), (“AzurRx” or the “Company”), a clinical stage biopharmaceutical company specializing in the development of...
AzurRx_Logo_CMYK.jpg
AzurRx BioPharma Doses First Patient In Phase 2 Clinical Trial of Niclosamide for the Treatment of COVID-19 Gastrointestinal Infections
June 07, 2021 07:00 ET | AzurRx BioPharma, Inc.
“RESERVOIR” trial to evaluate niclosamide’s ability to target SARS-CoV-2 in the GI tract Topline trial data expected in Q1 2022 BOCA RATON, Fla., June 07, 2021 (GLOBE NEWSWIRE) -- AzurRx...